The DCA Story
An Immunomodulator Between Communism and Capitalism
The discovery of the effect of deoxycholic acid as an immunomodulator in 1968 was due to the Czech biochemist Dr. Bohuslav Vlcek. He has devoted his life to academic research – a variety of his publications and patents underline this.
Dr. B. Vlcek was a member of the Academy of Sciences. He worked professionally with celebrities such as Nobel laureate Prof. Heyrovsky – both shared a time together at the Institute of Hygiene, Prague.
As is so often the case, he succeeded in discovering the immunological effect of deoxycholic acid by chance. At this time …
… he was a high-ranking scientist in biochemistry at Charles University in Prague. He ordered research into the effects of DCA as an immunomodulator in 1969-1974 in a five-year plan.
However, due to political quarrels and infighting, he had to leave the Czech Republic in 1974 as part of the rising popularity of DCA and go to the West. But this attempt to gain a foothold in “capitalism” in the leap over the iron curtain failed. He was too early for a world that was then chemically enthusiastic about the leap into the plastic age.
Dr. Bohuslav Vlcek died in 1998. Since then, his son Radim Vlcek has continued his work.
The Owner – Radim Vlcek
Legal ownership and management of the DCA project
As the owner of the DCA project – Radim Vlcek – I grew up with DCA as the son of the inventor. In my youth, I experienced the effects of DCA first-hand – my father’s first human experimental carnickel after his self-experiments. Thank God. I grew up with immunomodulation by deoxycholic acid.
I went on my professional career as a therapist, trainer, coach and organizational developer, because I was more passionate about working with people than with things.
But with the death of my father in 1998 …
… his colleagues, fans and customers approached me – with the wish to complete his work. I developed the use of DCA as an immunomodulator even more into the practical and especially into the field of prevention. Because the best drug is the one we don’t need.
DCA has therefore, not only literally, gone into my blood. The know-how of using DCA in medical treatment is a simple practical reality for me – since my childhood. Without this background of experience, I wouldn’t write these lines.
The beneficiaries – doctors and patients
The silent users with humanity
The effect of DCA as an immunomodulator is widely known in professional circles. This includes researchers, doctors, naturopaths and pharmacists alike.
Most, however, are wary of making known about their affinity or even practical work with DCA. This is simply because the legal hurdles for the use of deoxycholic acid in patients can only be overcome in some cases. In Germany sometimes as a pharmacist’s prescription, sometimes in off-label use.
But DCA is being used in many countries …
… around the world. But soft-footed I receive feedback of the effects that the treaters have in their practices. In some cases from Germany, in others from countries of the world, where it is easier to carry out new therapies.
And that feedback keeps me going on. Because here I see the importance and usefulness of DCA-based immunomodulation for patients, if it is carried out professionally.
The Developers – Research and Pharmaceutical Industry
The change of consciousness to ecology and synergy
There are several scientific publications and clinical studies on the effect of deoxycholic acid as an immunomodulator. The latter were mainly carried out in cases of viral diseases. In addition, there are more and more patents on certain uses of deoxycholic acid.
Many clinical studies on DCA have been going on for a long time, so their integration with the latest research results would make sense. The current DCA research has been gaining momentum in recent years. However, even these first clinical studies on DCA as an immunomodulator do not lose their significance for the behavior of deoxycholic acid in the immune process.
In the last millennium, deoxycholic acid was still too far from the mainstream for the pharmaceutical giants. Medium-sized companies would have liked to have joined, also because …
… their portfolio has in some cases high synergies for DCA-based treatment. But they would have been crushed by the immense cost of introducing a new drug into the market. Until recently, the use of DCA in practice remained a quiet act in the field of complementary medicine. Far below the potential that deoxycholic acid can develop in immunology.
In recent years, however, small progressive companies have launched new uses of deoxycholic acid. All based on their choleretic effect and function in fat metabolism. Although this is far from its immunological effect, the usefulness and approval of deoxycholic acid as an active ingredient has been achieved.
Circumstances such as the Corona crisis in 2020 require a faster rethink. Since I was born more than 50 years ago, the world’s population has doubled and diseases are endangering our entire economic system. Therefore, I think that evolution is too slow and we need accelerated steps to maintain a livable world for us and our descendants. Now is the time to act and to dare to do something new – because standstill is currently the biggest risk.
Publications and patents: DCA immunomodulator
DCA potentiates the immune response
Publication: Potentiation of the immune response with deoxycholic acid (Vlcek, Karls-Univ., CSSR, 1972) – Pub. at DCA Vlcek
GA regulate non-specific immune system
Publikation: Bile Acids Activated Receptors Regulate Innate Immunity (Fiorucci, Univ. of Perugia, Italy, 2018)
DCA in wound healing
Patent: Verwendung von Desoxycholsäure bei Wundheilungsstörungen (Dr. Müller, BRD, 1985)
DCA activates kupffer cells (macrophages)
Publikation: Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages (Ljubuncic, Technion-Israel Institute of Technology, Israel, 1996)
Influencing the immune response with DCA
Publikation: Affecting the immunity response with deoxycholic acid (Sborni Lekar, Chyle, CSSR, 1982)
DCA acts in natural cancer defense
Publikation: Evidence of the participation of deoxycholate in cancer immunity (Charles Univ., B. Vlcek, CSSR, 1971) – Pub. bei DCA Vlcek
Bile acids can act antiviral
Patent: Method and composition for the treatment and prevention of viral infections (Health Lab Service Board, Great Britain, 1990)
Macrophages are stimulated by GA
Publikation: Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders (Fiorucci, Univ. of Perugia, Italy, 2020)
DCA investigated to counter stomach cancer
Publikation: Deoxycholic acid inhibits the growth of BGC-823 gastric carcinoma cells via a p53‑mediated pathway (Yang, Henan Univ., China, 2015)
DCA as a steroidal immunopromotor
Publication: Perspectives of steroidal immunopromoters (Vlcek, Karls Univ., CSSR, 1974) – Pub. at DCA Vlcek
GA regulate immune defenses and inflammations
Publikation: Emerging roles of bile acids in mucosal immunity and inflammation (Chen, The Scripps Research Institute, USA, 2019)
DCA modulates inflammatory processes
Publikation: Microbial metabolite deoxycholic acid controls Clostridium perfringens-induced chicken necrotic enteritis through attenuating inflammatory cyclooxygenase signaling (Wang, University of Arkansas, USA, 2019)
DCA effects on herpes
Publication: For the treatment of herpes zoster with deoxycholic acid (Dr. Bradna, Hospital Kutna Hora, 1983, CSSR) – Pub. at DCA Vlcek
GA active in the immune system and inflammations
Publikation: Counter-regulatory role of bile acid activated receptors in immunity and inflammation (Fiorucci, University of Perugia, Italy, 2010)
DCA suppresses tumor growth
Publikation: Deoxycholic acid modulates the progression of gallbladder cancer through N 6-methyladenosine-dependent microRNA maturation (Lin, Shanghai Jiao Tong Univ., China, 2020)
Gallic acids stimulate macrophages
Patent: Immunmodulierende Zusammensetzungen aus Galle (Imutec Corp, Canada, 1996 & 2003)
DCA as Agent in Cancer Immunity
Publication: Toxicity of deoxycholate at pH below 7-3 as a potential cancerostatic property (Vlcek, Karls-Univ., CSSR, 1970) – Pub. at DCA Vlcek
GA control the immune system
Publikation: The Immunomodulatory Role of Bile Acids (Sipka, Univ. of Debrecen, Hungary, 2014)
DCA against gallbladder cancer
Publikation: Deoxycholic acid modulates the progression of gallbladder cancer through N 6-methyladenosine-dependent microRNA maturation (Lin, National Scienc Foundation of China, 2020)
Tackling bowel cancer with UDCA
Patent: Composition for the prevention or treatment of gastric cancer containing urso-deoxycholic acid as an active ingredient (Chosun University, South Korea, 2011)
Livestock feed with DCA supports immune defenses
Patent: Futter und Futterzusatzmittel mit einer verbesserten Resistenz gegen Krankheiten wie Pseudorabies für Vieh, Geflügel und Fisch (National Federation Agriculture, Japan, 1995)
DCA treatment of herpes recurrences
Publication: Deoxycholic acid in the treatment of recurrent herpes Labialis (Chyle, Karls-Univ. Prague, CSSR, 1975) – Pub. at DCA Vlcek
Candida reduced by DCA
Publikation: Secondary bile acids inhibit Candida albicans growth and morphogenesis (Guinan, Oxford University Press, Great Britain, 2018)
Deoxycholic acid regenerates skin
Patent: Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening (LG Household & Health Care Ltd., South Korea, 2015)
DCA heparin against inflammation
Patent: Composition for preventing or treating of inflammatory diseases comprising novel desulfated heparin-deoxycholic acid derivates (Kyungpook University, South Korea, 2012)
UDCA as a cancer drug?
Patent: Compound having anti-cancer effect and method for preparation thereof and application thereof (3D Medicines, China, 2017)